Kura Oncology: Less Than Nothing By The First Readout
Gary Aquilina is an independent research analyst with a BA in Business Enterprise who has been analyzing stocks for personal knowledge since 2020. Over the years, he has taken a particular interest in the world of pharmaceuticals and biotech, looking to find deep value plays sitting outside the box, whilst also generally keeping an eye on macroeconomic and stock market trends, and fundamentals which shape their valuations, especially to spot undervalued picks.Closely associated with Jordan Aquilina.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
